Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation
- 25 December 2006
- journal article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 11 (6) , 454-460
Abstract
Definitive chemoradiation with cisplatin (CDDP) and 5-fluorouracil (5FU) has been playing an important role in the treatment of esophageal cancer, but some patients are not curable or have recurrent lesions. However, few chemotherapeutic regimens are available for such patients. Docetaxel and nedaplatin are active for esophageal cancer. We conducted a dose-escalation study of docetaxel and nedaplatin as second line-chemotherapy after definitive chemoradiation in patients with relapsed or refractory squamous cell carcinoma of the esophagus after chemoradiation. Nedaplatin was administered on day 1 and docetaxel was administered on days 1 and 15, every 4 weeks. Dose escalation was based on the dose-limiting toxicity (DLT) observed during the first cycle. Twelve patients were enrolled. At a docetaxel dose of 30 mg/m2 and a nedaplatin dose of 80 mg/m2, one grade 4 neutropenia occurred and caused one treatment break longer than 2 weeks, but there were few DLTs. At doses of 35 and 80 mg/m2, respectively, two grade 4 neutropenias and one grade 2 thrombopenia occurred and caused three treatment breaks longer than 2 weeks. Therefore, the maximum tolerated dose was established at this dose level. Two grade 3 anorexias and one grade 3 nausea occurred, but other non-hematological toxicities were generally mild. Responses were seen in one-fourth of the 12 patients, including one complete remission. The recommended doses of docetaxel and nedaplatin were 30 and 80 mg/m2, respectively. This combination could be a potential second-line treatment for this target population.Keywords
This publication has 29 references indexed in Scilit:
- A phase II study of single-agent docetaxel in patients with metastatic esophageal cancerAnnals of Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- A New Combination Chemotherapy with Cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for Advanced Esophageal Cancers.Internal Medicine, 1999
- In VitroPhase II Comparison of the Cytotoxicity of a Novel Platinum Analog, Nedaplatin (254-S), with That of Cisplatin and Carboplatin against Fresh, Human Cervical CancersGynecologic Oncology, 1998
- Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the EsophagusNew England Journal of Medicine, 1997
- A Comparison of Multimodal Therapy and Surgery for Esophageal AdenocarcinomaNew England Journal of Medicine, 1996
- Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the EsophagusNew England Journal of Medicine, 1992
- Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of TaxolJNCI: Journal of the National Cancer Institute, 1991
- SYNTHESIS OF (GLYCOLATO-O,O′)DIAMMINEPLATINUM(II) AND ITS RELATED COMPLEXESChemistry Letters, 1986